Antibe: Canaccord Raises Price Target After Q4 Results

On June 28th,  Antibe Therapeutics (TSX: ATE) reported their fourth quarter and year-end financials. The company announced full-year revenue of $9.7 million, which came in flat year over year, with a larger than expected net loss of $26.3 million. The company ended the year with $72 million in cash.

The company has seven analysts covering it, with a weighted 12-month price target of C$14.55, or an almost 300% upside. Out of the seven analysts, one has a strong buy rating while the other six have buy ratings. The street high comes from Brookline Capital with a C$20.60 price target and the lowest sits at C$7.00 from Raymond James.

Canaccord Genuity raised its 12-month price target to C$15.00, up from C$14.50, while reiterating their speculative buy rating. Tania Gonsalves, Canaccord’s analyst, says that the company left 2021, “well-capitalized and de-risked.”

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

For the fourth quarter and full-year results, Gonsalves says that there were no real deviations into the results and they came generally in line with their expectations. For the fourth quarter, Citegenix revenue came in slightly higher at $3 million versus their $2.6 million estimate. Meanwhile R&D expenses came in slightly higher at $3.1 million versus their $2.5 million estimate. She adds, “as a clinical stage biotechnology company, quarterly financials are not a materially impactful event.”

The most important thing she says is after the two raises the company has $72 million in cash, which by their estimates “will be sufficient to fund operations for over two years, including otenaproxesul’s full ~$60.0M adaptive Phase 2/3 program.” She then refers to this quarter as a very productive de-risking quarter for the company.

Gonsalves says that the collaboration with Dalriade will help drive pipeline expansion. The team at Dalriada has 50 scientists and specializes in developing small-molecule drugs. She says it will help “Accelerate screening, selection, and advancement of drug candidates for IND-enabling studies.”

Below you can see Canaccord’s changes to estimates, which were used to get to the new price target.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

Netflix: Canaccord Increases Subscriber Growth Estimates

Last week, Netflix (NASDAQ: NFLX) announced that Universal and Netflix have extended their exclusive license...

Friday, July 23, 2021, 04:43:00 PM

Canopy Growth: Analysts Expect Q2 Revenues Of $142.5 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal...

Thursday, November 4, 2021, 03:16:00 PM

BMO Drops Cenovus Energy Price Target To $6.00 From $7.50

This morning BMO lowered its 12-month price target on Cenovus Energy (TSX: CVE) to C$6.00...

Friday, October 30, 2020, 11:22:00 AM

Canaccord Lowers Aurora Cannabis Price Target To $5 Following Q2 Earnings

On February 10th, Aurora Cannabis (TSX: ACB) reported its fiscal second quarter 2022 results. The...

Sunday, February 13, 2022, 05:16:00 PM

Haywood Initiates On Bragg Gaming With $3.00 Price Target

Earlier this week, Haywood Capital Markets initiated coverage on Bragg Gaming (TSX: BRAG) with a...

Wednesday, April 28, 2021, 03:21:00 PM